PolyMedica - 84% vom free float *short*
moign,
PLMD ist im S&P600 und hat knapp 60% in den letzten 4 Wochen verloren.
P/B = 1
P/S = 0.73
P/E = 5.29
(Daten aus yahoo)
=> und der Hammer: 84% des free float sind *short*(8.57Mio Stück) => uiuiuiui, wer dreht den da am *Rad*????
=> sie sollten von der nasdaq an die nyse wechseln, dies ist nicht erfolgt => ein *Rutscher* => ein Kommentar von meinen Kumpels
=========================================
PolyMedica Pandemonium
The New York Stock Exchange's sudden and unexplained decision not to list the medical products maker's stock has investors in a tizzy. Unfortunately, even the company seems unclear as to what is going on. The best clues involve unnamed sources discussing an apparent FBI investigation into billing practices and the unusually high interest of short sellers in the company's stock.
By Dave Marino-Nachison (TMF Braden)
July 23, 2001
Shareholders of medical products company PolyMedica (Nasdaq: PLMD) had all weekend to fret over what would happen to their shares after the company released some vague, troubling news on Friday. But when more information became available today, and the stock quickly lost a quarter of its market value, there was more rejoicing on Wall Street than despair.
Why's that? Because, according to Market Guide data, nearly 80% of the company's "float" -- the total number of shares a company has on the market -- is held short, meaning investors have borrowed and sold shares hoping they will fall in value, allowing them to repurchase at a lower price and return them to the lender, pocketing the difference. (For more on this practice, check out our Fool FAQ area on the subject.)
That's an unusually high "short interest," and cautious investors might take that as a sure sign of a stock to avoid. But the company, its financial statements suggest, is no dog: PolyMedica's chairman and CEO pointed to compounded annual growth in sales and earnings per share in excess of 50% per year since fiscal 1997 in a July 9 statement.
So what's happening today? Here's the background: In the aforementioned July 9 news release, the New York Stock Exchange announced that the company would change its listing from the Nasdaq to the NYSE, a move sometimes considered a feather in a corporate cap. "We are proud to welcome PolyMedica Corporation to the large group of preeminent healthcare companies on the New York Stock Exchange," NYSE Chairman Dick Grasso said in the release.
Today was to be the day of the changeover. On Friday evening, however, the company surprised investors by saying the NYSE "changed its decision to list the company, but has not informed the company of its reason for doing so."
Cut to Monday morning, and investors still don't know the reasons for the NYSE's decision. While the exchange does have specific listing standards, it reserves the right to "deny listing or apply additional or more stringent criteria based on any event, condition, or circumstance that makes the listing of the company inadvisable or unwarranted in the opinion of the exchange." That's left observers with little they can reasonably do but worry and speculate.
Probably the best information investors have to go on at present comes from TheStreet.com, which reported today and in March that the FBI has questioned former employees of PolyMedica's Liberty Medical Supply unit about its Medicare billing practices. But conflicting accounts of the status of the alleged investigation only confuse the picture, and both the company and government are little help.
Feds rarely comment on ongoing investigations, while PolyMedica's latest 10-K filing mentions an "alleged [FBI] investigation" only in passing and in the context of ongoing lawsuits reportedl